<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800471</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00095543</org_study_id>
    <nct_id>NCT04800471</nct_id>
  </id_info>
  <brief_title>Improving Glycemic Control in DM2 Patients in the Ambulatory Setting</brief_title>
  <official_title>Improving Glycemic Control and Clinical Outcomes in DM2 Patients in the Ambulatory Setting, a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      More than 10.5% of the US population has diabetes mellitus. The objective of this pilot study&#xD;
      is to evaluate whether smart insulin pens combined with CGM devices can improve glucose&#xD;
      control in patients with type 2 diabetes (T2D)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hyperglycemia</measure>
    <time_frame>3 months</time_frame>
    <description>Change in HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hyperglycemia</measure>
    <time_frame>6 months</time_frame>
    <description>Change in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hypoglycemia</measure>
    <time_frame>3 months</time_frame>
    <description>Change in hypoglycemic episodes (CGM glucose &lt;70 mg/dl for at least 15 min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hypoglycemia</measure>
    <time_frame>6 months</time_frame>
    <description>Change in hypoglycemic episodes (CGM glucose &lt;70 mg/dl for at least 15 min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinically significant hypoglycemia</measure>
    <time_frame>3 months</time_frame>
    <description>Change in clinically significant hypoglycemic episodes (CGM&lt;54 mg/dl at least 15 min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinically significant hypoglycemia</measure>
    <time_frame>6 months</time_frame>
    <description>Change in clinically significant hypoglycemic episodes (CGM&lt;54 mg/dl at least 15 min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Time in Range (70-180 mg/dl)</measure>
    <time_frame>3 months</time_frame>
    <description>Change in CGM glucose Time in Range (70-180 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Time in Range (70-180 mg/dl)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in CGM glucose Time in Range (70-180 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Time Below Range (&lt;70 mg/dl)</measure>
    <time_frame>3 months</time_frame>
    <description>Change in CGM Time Below Range (&lt;70 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Time Below Range (&lt;70 mg/dl)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in CGM Time Below Range (&lt;70 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Time Above Range (&gt;180 mg/dl)</measure>
    <time_frame>3 months</time_frame>
    <description>Change in CGM Time Above Range (&gt;180 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Time Above Range (&gt;180 mg/dl)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in CGM Time Above Range (&gt;180 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glucose Variability</measure>
    <time_frame>3 months</time_frame>
    <description>Change in Coefficient of Variation (CV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glucose Variability</measure>
    <time_frame>6 months</time_frame>
    <description>Change in Coefficient of Variation (CV)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Smart insulin pens and CGM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Point of Care Glucose Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this group will be monitored by point of care glucose values</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Smart insulin pens and CGM</intervention_name>
    <description>Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices</description>
    <arm_group_label>Smart insulin pens and CGM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Point of Care Glucose Group</intervention_name>
    <description>Participants in this group will be monitored by POC glucose values.</description>
    <arm_group_label>Point of Care Glucose Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Insulin-treated patients with DM2 (treated with basal-bolus insulin regimens (MDI), Â±&#xD;
        non-insulin medications) and Uncontrolled glycemic control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of type 1 DM (DM1)&#xD;
&#xD;
          -  Pregnant Patients&#xD;
&#xD;
          -  Extensive skin changes/disease or allergies that preclude wearing the CGM sensor&#xD;
&#xD;
          -  Subjects who have end-stage renal disease requiring dialysis&#xD;
&#xD;
          -  Significant psychiatric illness or any other condition rendering the subject incapable&#xD;
             of understanding the objectives and potential consequences of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>William Scott</last_name>
    <phone>4106057000</phone>
    <email>william.scott5@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baltimore VA Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William 'Scott</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Ilias Spanakis</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

